Salem Partners

Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences.

Form Bio is a biotechnology company that addresses data, computational, and technical challenges in the life sciences sector. It offers a comprehensive platform designed to empower scientific discovery by providing end-to-end integration of the research process. The platform features a range of tools including workflows, data management, collaboration, data visualization, and a workflow catalog, catering to various stakeholders such as lab directors, biotech firms, pharmaceutical companies, and academic institutions. By combining intuitive software applications with an open and adaptable collaborative environment, Form Bio enables scientists to efficiently leverage the growing abundance of data and computing power in their research efforts.

OncoNano Medicine, Inc. is a biotechnology company focused on developing pH-activated compounds and nanotechnology-enabled fluorescent probes to enhance cancer surgery. Founded in 2014 and based in Southlake, Texas, the company aims to improve tumor visualization during surgical procedures by utilizing the variability of pH in diseased tissue. Its flagship program, ONM-100, specifically targets tumor acidosis, allowing for a clear distinction between cancerous and healthy tissues. This technology provides surgeons with the tools to excise tumors more accurately and manage cancer treatment effectively during and after surgery. OncoNano Medicine's innovative approach aims to enhance surgical outcomes and improve patient care in oncology.

Fabric is a cloud platform that enables customers to manage editorial, technical, and other metadata for television shows, movies, documentaries, games, and other media. With Fabric, you can easily connect your catalogue to new platforms, transform internal data processes, and deliver dramatically improved viewer and user experiences.

Levels Beyond, Inc. is a software company based in Denver, Colorado, specializing in media management and workflow solutions. The company has developed the Reach Engine platform, which enables production teams and media manufacturers to efficiently find, organize, produce, and share digital media. This comprehensive platform facilitates video content creation and curation, while also providing cloud services that integrate seamlessly with existing media workflows. Levels Beyond offers a content management system that allows for publishing across multiple platforms, serving various sectors including media and entertainment, sports, marketing, and new media distribution. Founded in 2000, the company has established strategic partnerships, including one with Verizon Digital Media Services, to enhance its service offerings.

OncoNano Medicine, Inc. is a biotechnology company focused on developing pH-activated compounds and nanotechnology-enabled fluorescent probes to enhance cancer surgery. Founded in 2014 and based in Southlake, Texas, the company aims to improve tumor visualization during surgical procedures by utilizing the variability of pH in diseased tissue. Its flagship program, ONM-100, specifically targets tumor acidosis, allowing for a clear distinction between cancerous and healthy tissues. This technology provides surgeons with the tools to excise tumors more accurately and manage cancer treatment effectively during and after surgery. OncoNano Medicine's innovative approach aims to enhance surgical outcomes and improve patient care in oncology.

RightsLine is a global rights and royalties management software company that specializes in providing a comprehensive platform for intellectual property (IP) owners to effectively manage and monetize their content throughout its lifecycle. The company's innovative technology tools are designed to serve a diverse range of industries, including media and entertainment, gaming, publishing, consumer products, life sciences, and high tech. RightsLine offers features such as real-time availability, pipeline management, contract visibility, and inventory management, enabling finance, legal, operations, and strategy teams to gain a complete understanding of their content's rights, royalties, contracts, and sales opportunities. This robust SaaS solution simplifies complex rights management processes, enhancing the ability of clients to maximize the value of their IP assets.

Lucid Sight, Inc. is a computer software company based in Los Angeles, California, that specializes in the design and development of virtual reality games and software applications. Founded in 2015, the company focuses on creating immersive entertainment experiences using blockchain, augmented reality, and virtual reality technologies. Lucid Sight develops multiplayer adventure and sports games, aiming to provide engaging interfaces for gamers. Additionally, the company offers tools and plug-ins for virtual reality developers and innovative monetization and marketing platforms for brands and game developers. Through its catalog, Lucid Sight serves a diverse clientele, including developers and advertisers, by leveraging emerging technologies to enhance gaming and marketing experiences.

RightsLine is a global rights and royalties management software company that specializes in providing a comprehensive platform for intellectual property (IP) owners to effectively manage and monetize their content throughout its lifecycle. The company's innovative technology tools are designed to serve a diverse range of industries, including media and entertainment, gaming, publishing, consumer products, life sciences, and high tech. RightsLine offers features such as real-time availability, pipeline management, contract visibility, and inventory management, enabling finance, legal, operations, and strategy teams to gain a complete understanding of their content's rights, royalties, contracts, and sales opportunities. This robust SaaS solution simplifies complex rights management processes, enhancing the ability of clients to maximize the value of their IP assets.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on the design and development of innovative treatments for diseases related to abnormal blood vessel growth, specifically through the use of short biomimetic anti-angiogenic and anti-lymphangiogenic peptides. The company's lead candidates, including AXT107, AXT201, AXT301, and AXT501, target conditions such as diabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion, which are among the leading causes of blindness. Additionally, AXT201, AXT301, and AXT501 are being explored for their potential in treating various solid tumors. AsclepiX leverages advanced computational biology, bioinformatics, and the latest developments in biomaterials to enhance drug delivery systems, aiming to create long-lasting biodegradable nanoparticles that can effectively deliver its therapeutic peptides. Incorporated in 2011 and based in Baltimore, Maryland, AsclepiX Therapeutics is committed to addressing unmet medical needs in ophthalmology, oncology, and other diseases driven by angiogenesis and lymphangiogenesis.

OncoNano Medicine, Inc. is a biotechnology company focused on developing pH-activated compounds and nanotechnology-enabled fluorescent probes to enhance cancer surgery. Founded in 2014 and based in Southlake, Texas, the company aims to improve tumor visualization during surgical procedures by utilizing the variability of pH in diseased tissue. Its flagship program, ONM-100, specifically targets tumor acidosis, allowing for a clear distinction between cancerous and healthy tissues. This technology provides surgeons with the tools to excise tumors more accurately and manage cancer treatment effectively during and after surgery. OncoNano Medicine's innovative approach aims to enhance surgical outcomes and improve patient care in oncology.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. Founded in 2008, Sebacia aims to provide innovative alternatives to traditional topical and systemic drugs used to treat acne. The company's technology utilizes a formulation of gold microparticles that are applied to the skin and subsequently treated with a standard dermatology laser. This method selectively targets the skin structures involved in acne, addressing unmet needs in dermatology. Sebacia's patented technology was initially developed at Rice University and further advanced in collaboration with researchers at the Wellman Center of Photomedicine at Massachusetts General Hospital.

Lucid Sight, Inc. is a computer software company based in Los Angeles, California, that specializes in the design and development of virtual reality games and software applications. Founded in 2015, the company focuses on creating immersive entertainment experiences using blockchain, augmented reality, and virtual reality technologies. Lucid Sight develops multiplayer adventure and sports games, aiming to provide engaging interfaces for gamers. Additionally, the company offers tools and plug-ins for virtual reality developers and innovative monetization and marketing platforms for brands and game developers. Through its catalog, Lucid Sight serves a diverse clientele, including developers and advertisers, by leveraging emerging technologies to enhance gaming and marketing experiences.

Femasys Inc. is a biomedical company based in Suwanee, Georgia, dedicated to enhancing women's healthcare through innovative medical devices. Established in 2004, Femasys focuses on developing non-surgical solutions in reproductive health, particularly with its lead products, FemBloc and FemaSeed. FemBloc is the first non-surgical option for permanent birth control, while FemaSeed is designed for directed sperm delivery in infertility treatments. The company also markets FemVue, a device for assessing fallopian tubes via ultrasound, as a key offering in the United States. Additionally, Femasys is developing a novel tissue sampling technology intended for use alongside its other products in clinical settings, aiming to improve patient care and health economics for women.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.